uniQure N.V. (QURE)

uniQure NV's stock experienced several events in the past six months. On November 10, 2025, shares declined following the Q3 2025 earnings announcement, despite increased revenue but a net loss. On November 11, 2025, the stock traded up due to perceived encouraging FDA designation. On December 4, 2025, shares dropped after the FDA indicated that Phase I/II trial data for AMT-130 were unlikely to serve as the main evidence for a BLA submission. On December 9, 2025, Mizuho lowered its price target on uniQure. On January 9, 2026, the stock rose after uniQure announced a Type A meeting with the FDA to discuss the BLA data package for AMT-130. On January 12, 2026, uniQure N.V. shares were down. Analyst ratings in November 2025 saw target price cuts from Royal Bank of Canada, HC Wainwright, and Wells Fargo & Company, while William Blair restated a "market perform" rating.

The provided information does not indicate any specific demand seasonality for uniQure's products or services. Demand for their treatments is likely driven by medical need rather than seasonal factors.

uniQure N.V. is a gene therapy company focused on developing treatments for rare and severe genetic diseases, operating in the Biotechnology industry within the Healthcare sector. Its key products include HEMGENIX for hemophilia B, which was the world's first approved gene therapy for hemophilia in 2022. Other pipeline candidates include AMT-130 for Huntington's disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, AMT-162 for amyotrophic lateral sclerosis (ALS), and AMT-240 for Autosomal Dominant Alzheimer's Disease. uniQure also collaborates with Bristol Myers Squibb on gene therapies for cardiovascular diseases.

uniQure N.V. is headquartered in Amsterdam, the Netherlands, and has operations in the United States, the Netherlands, and Switzerland.

uniQure's brand reputation has been influenced by developments related to AMT-130. Positive developments included topline data from the Phase I/II study of AMT-130, showing a slowing of disease progression, and the scheduling of a Type A meeting with the FDA. Challenges included the FDA's feedback that the Phase I/II trial data for AMT-130 were unlikely to serve as the main evidence for a BLA submission, and uniQure's voluntary pause of enrollment in the Phase 1 and 2 EPISOD1 trial for AMT-162 (ALS) due to a dose-limiting toxicity in one patient.

uniQure N.V.'s ownership is primarily institutional, with institutional investors holding approximately 59.69% to 65.16% of the stock. Insiders own about 2.21% to 2.7%, while public companies and individual investors hold around 5.47% to 32.63%. Major institutional owners include Fmr Llc, Avoro Capital Advisors LLC, and BlackRock, Inc. Bv Foruniqure is the largest individual shareholder, owning 4.38 million shares, representing 7.03% of the company.